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romodomain and extra terminal (BET) proteins comprise the ubiquitously expressed BRD2, BRD3, BRD4 and the testes specific BRDT.
1,2 These multipurpose proteins contain tandem N-terminal bromodomains that bind acetylated lysine residues of histone (and non-histone) proteins and other protein modules, such as the extra terminal domain, and in some (BRD4, BRDT), a C-terminal domain. They also mediate a number of effects including transcriptional activation via recruitment of other partner proteins. 3 Inhibitors of these proteins are emerging as exciting new therapies for the treatment of hematologic and solid malignancies, offering the possibility of specifically targeting epigenetic readers. We and others have already demonstrated the preclinical efficacy of BET inhibitors in acute myeloid leukemia (AML), [4] [5] [6] while several other papers have documented similar efficacy in myeloma, 7 non-Hodgkin lymphoma, 8 and acute lymphoblastic leukemia. 9 These observations have led to several clinical trials that are currently underway to confirm the efficacy of these drugs in AML and other malignancies. Even though the most mature trials have recently reported limited objective responses of monotherapy in heavily pre-treated AML, lymphoma and myeloma patients, [10] [11] [12] early data suggest that combination therapies with other small molecules or more conventional cytotoxic agents might be particularly promising. [13] [14] [15] BET proteins have multiple functions. Amongst these, and considered critical for the maintenance of malignant transcription, they are implicated in the regulation of large or "super" enhancers that control a number of critical genes, including oncogenes pivotal for the maintenance of leukemia, such as BCL-2, IRF8, and c-MYC. Their downregulation upon treatment with small molecule BET inhibitors at least partially explains the effects of BET inhibition observed in hematologic and solid malignancies. 4, 13, 15, 16 However, despite several ongoing clinical trials, we know surprisingly little about the consequences of disrupting BET protein function in normal tissues. In this issue of the Journal, Wroblewski et al., 17 therefore, address a highly relevant topic and describe the effects of the prototypic BET inhibitor JQ1 on normal hematopoiesis. Surprisingly, upon JQ1 treatment, Wroblewski et al. identify an increase in phenotypic HSC proliferation and mobilization in mice. In addition, these effects seem sustained, and functionally, in the setting of competitive transplantation, JQ1 treated HSC appear to contribute more to hematopoiesis in primary and, importantly, in secondary recipients with no evidence of exhaustion, albeit follow up was only for 12 months following transplantation. This increased proliferation does not enhance radiosensitivity. On the contrary, JQ1 treated mice show faster count recovery following sublethal irradiation compared to untreated controls. Although the authors have not studied potential underlying mechanisms, they postulate that the effects might be mediated by JQ1 dependant suppression of Myb, 18 given the phenotypic similarity between JQ1 treatment and a mouse model of reduced Myb activity. 19 Due to its pharmacokinetic properties, JQ1 does not lead to sustained target inhibition, and due to its limited efficacy in pre-clinical models, JQ1 has never been tested in clinical trials. 20 Therefore, whether JQ1 induced expansion of the normal HSC pool described here is a "class effect" shared by more potent BET inhibitors needs to be carefully addressed by further studies. This is further called into question by the toxicity reports from the clinical trials that have consistently reported hematologic toxicity, in particular, a dose-dependent, non-cumulative, reversible thrombocytopenia, 10, 11 and by opposing reports in the literature regarding the effects of BET inhibition on normal HSC. In a mouse model of controlled BRD4 inhibition, using an inducible transgenic shRNA, Brd4 silencing caused a significant reduction in Lineage-Sca-1 + c-kit + hematopoietic stem cells 12 weeks after hematopoietic reconstitution. 21 However, as RNAi would not only lead to almost complete loss of Brd4, but would also target the non-bromodomain dependent functions of the protein, differences between these models, where inhibitors would only intermittently target the bromodomains, might be expected.
Certainly the possibility that BET inhibitors, in addition to exerting antitumor effects, could enhance recovery of normal hematopoiesis, especially after combination chemotherapy, is intriguing and could open up new avenues for the use of BET inhibitors in clinical practice (Figure 1 ). Other areas of utility for BET inhibition, as suggested by Wroblewski et al., 17 could include mobilization of peripheral blood (PB) HSC from donors who fail more standard approaches. However, validation of this study with orally available BET inhibitors and specific testing of these hypotheses will be necessary.
BET inhibitors might also have a role against acute graftversus-host disease (GvHD) and, in fact, were initially designed as immunosuppressives. Wroblewski et al. 17 and others have shown that BET inhibitors impair T-cell function. Specifically, Wroblewski et al. 17 find that JQ1 treatment causes increased apoptosis in T cells, and this is associated with reduced expression of the antiapoptotic BCL-2 as measured by RT-qPCR. Others have demonstrated that treatment with I-BET151 results in a reduction in the secretion of IL-6, TNF-α, and IL-12 by stimulated dendritic cells (DCs). 22 Both T cells and DCs are important mediators of GvHD in recipients of allogeneic stem cell transplant, suggesting that BET inhibitors may serve as a prophylactic therapy against acute GvHD. Again, the results suggested by the pre-clinical models need to be validated in clinical trials and the benefits must be weighed against the risks of hematologic toxicity, particularly thrombocytopenia and neutropenia.
In conclusion, BRD4/BET inhibition is becoming a novel and exciting treatment option in many hematologic and solid malignancies, and may have novel promising effects in bone marrow transplantation. However, little is known about the effects of such treatment in normal tissues and an ongoing concern has been about the size of the therapeutic window. However, some reassurances are provided by the studies performed by Wroblewski et al. that have addressed this issue and suggest potentially beneficial effects on normal hematopoiesis; further studies are warranted to validate and extend these findings. However, a note of potential caution comes from models of BET inhibitor resistance that suggest that under the continuous and sustained selective pressures of BET inhibition, a small proportion of leukemic stem cells (LSC) survive and that over time these cells become the dominant clone.
Mechanistically, this appears to occur through the activation of the ancillary WNT/β-Catenin pathway that allows escape from BET inhibition. Importantly, resistance to BET inhibition in this model is only partially reversible on suspending I-BET. 23 The evidence from the Fong et al. study, 23 coupled with the evidence emerging from clinical trials and early study of combination therapy, strengthens the argument for developing rational combination strategies of BET inhibitors and other agents for patients with hematologic and solid malignancies. The Wroblewski et al. study 17 promises an unexpected but welcome positive effect on normal hematopoiesis. haematologica | 2018; 103(6) Figure 1 . Effects of BET inhibition on normal and diseased hematopoiesis. Hematopoiesis is a finely regulated process precisely balancing hematopoietic stem cell (HSC) self-renewal and differentiation. In a preclinical model, BET inhibition seems to affect this tightly regulated mechanism, resulting (as shown) in increased HSC self-renewal and mobilization but also altered lymphocyte differentiation. Advantageous effects may occur on mobilization of peripheral blood HSC donors or could enhance restoration of normal hematopoiesis after chemotherapy through effects on normal HSC and by altering the balance between normal and leukemic stem cells (LSCs). However, caution is required due to the demonstrated emergence of resistance within the leukemia stem cell compartment under sustained BET inhibition in recent preclinical models. 10.3324/haematol.2018.193847 R esearch on primary patient cells is a compelling challenge for scientists. Although initially limited to short experiments over hours or days, engrafting these primary human cells in immunodeficient mice today allows even more informative investigation to be carried out over weeks and months. This experiment is fascinating, probably first because it gives rise to personal and moral questions about the patient's avatar. Also, in basic research, the xenograft is the model to be used to reveal the stemness properties of a certain population of cancer cells. 1 Although today there are some ex vivo alternatives, the xenograft remains the gold standard technique to study cancer stem cells which are responsible for cancer initiation propagation, maintenance and evolution. Uncovering the presence of primary human leukemic cells in a sample of mouse tissue 10-16 weeks after injection, demonstrating the initial engraftment of leukemia initiating cells (LICs) causes an exhilarating sensation known to only a few lucky scientists. Absence of graft triggers the opposite sensation of complete disappointment, which has led several teams to focus their attention on this particular problem with the xenograft approach. In this issue of Haematologica, Krevvata et al. put forward fundamental new insights to help improve xenograft of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). 2 Myelodysplastic syndrome and acute myeloid leukemia are myeloid neoplasms that disrupt normal hematopoiesis. This group of myeloid leukemias could be considered as a continuum consisting of a multitude of different leukemias, including all possible myeloid abnormalities. This results in a wide range of severity and patient overall survival (OS). MDS patients have globally better OS than AML patients, and some MDS evolve inevitably towards AML. Interestingly, the first attempts at AML/MDS xenograft quickly revealed, through the repartition of samples engrafting and non-engrafting the mice, that the engraftment potential was perfectly linked with the aggressiveness of the leukemia, since AML samples are usually more easy to engraft than MDSs. 3, 4 Many independent studies have offered different reasons for engraftment failure, but none can satisfactorily explain it. Possible explanations are either related to the host immune environment or to the defect of the grafted cells or to the graft and host compatibility.
NSG-S mice for acute myeloid leukemia, yes. For myelodysplastic syndrome, no.
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The innate and adaptive immune response of the host environment is an obvious and very clear obstacle for the
